Rationale: Rifapentine has potent activity in mouse models of tuberculosis chemotherapy but its optimal dose and exposure in humans are unknown.
An obstacle to tuberculosis (TB) control is the long treatment duration (at least 6 mo) required for cure of drug-susceptible pulmonary TB. Potent regimens of shorter duration would facilitate treatment completion and therefore improve individual and public health (1) . Strategies for increasing regimen potency include development of new drugs and optimization of the use of existing drugs.
Of the drugs in current use, rifamycins hold promise for shortening treatment through pharmacodynamic optimization. Rifamycins have durable sterilizing activity against Mycobacterium tuberculosis, and the currently recommended 10 mg/kg dosage of rifampin, the most commonly used rifamycin, is at the low end of the dose-response curve (2) (3) (4) (5) (6) (7) (8) (9) . Historically, selection of this rifampin dose seems to have been influenced by cost in the setting of incomplete dose-finding studies (10) .
Rifapentine is a cyclopentyl ringsubstituted rifamycin. Compared with rifampin, rifapentine has a longer half-life and lower minimum inhibitory concentration against M. tuberculosis (11) (12) (13) (14) (15) . Preclinical studies using mouse models have shown that regimens containing daily rifapentine can cure TB after only 3 months of treatment (16) (17) (18) . A phase 1 clinical trial showed that rifapentine doses up to 20 mg/kg administered daily were well-tolerated and safe in healthy volunteers (19) . A previous phase 2 clinical trial found 10 mg/kg of daily rifapentine to be as safe as, but not more efficacious than, 10 mg/kg of daily rifampin during the first 8 weeks of combination TB chemotherapy (20) . We conducted a dose-ranging clinical trial to determine the optimal dose of daily rifapentine during the first 8 weeks (intensive phase) of combination treatment for pulmonary TB. Some of the results of this trial have been reported previously in the form of an abstract (21) .
Methods
This was a randomized, multicenter, partially blinded clinical trial. The primary end point was discontinuation of assigned treatment during the first 8 weeks (tolerability). The frequency and severity of adverse events were also determined (safety). Efficacy end points were sputum culture status at completion of intensive phase as assessed separately on solid and liquid culture medium, and time to stable culture conversion.
Setting, Population, and Design
Participants were enrolled at 18 sites (nine in North America, four in Africa, two in South America, two in Asia, one in Europe). Adults with suspected pulmonary TB and acid-fast bacilli detected by microscopy in a stained sputum specimen were eligible. Individuals were excluded if they had received more than 5 days of anti-TB treatment in the preceding 6 months, or had current or planned therapy in the subsequent 8 weeks with antiretroviral medications. Detailed eligibility criteria are in Table E1 of the online supplement. All participants underwent HIV testing. This study was approved by the Centers for Disease Control and Prevention and site institutional ethics review boards. Participants gave written informed consent.
Participants were randomly assigned to receive rifampin (z10 mg/kg) or rifapentine (z10, 15, or 20 mg/kg) administered once daily for 7 day per week, in addition to daily isoniazid, pyrazinamide, ethambutol, and pyridoxine for the intensive phase of TB treatment (8 wk) . Randomization was performed centrally, in 1:1:1:1 allocation between arms, stratified by the presence of cavitation on baseline chest radiograph and by enrollment site, and restricted to limit imbalance between arms to no more than two subjects (22) .
Dosages of isoniazid, rifampin, pyrazinamide, ethambutol, and pyridoxine were in accordance with published guidelines; additional details are in Table E2 (23). With respect to clinical care providers and participants, rifapentine dose was double-blinded but assignment of rifapentine versus rifampin was open-label because of different food requirements; mycobacteriology laboratory staffs were fully blinded with respect to treatment assignment. On at least 5 of 7 days per week, study medicines were administered by directly observed therapy. To increase rifapentine bioavailability, rifapentine regimens were administered within 1 hour after a high-fat meal (target, >28 g fat); rifampin regimens were administered mostly without food because food delays rifampin absorption (24, 25) . After completing intensive phase treatment, participants continued treatment with a conventional continuation phase regimen, typically isoniazid plus rifampin for 4 additional months (23) .
Information on symptoms, blood for alanine aminotransferase, bilirubin, creatinine, and complete blood count, and a sputum specimen were collected at baseline and at completion of 2, 4, 6, and 8 weeks of treatment. An additional sputum specimen was collected at Week 8. Sputa were collected monthly during continuation phase treatment unless two or more consecutive prior cultures were already negative for M. tuberculosis. At local site laboratories sputa were processed using conventional N-acetyl-L-cysteine-NaOH methods and cultured using both Lowenstein-Jensen solid media and BACTEC Mycobacterial Growth Indicator
At a Glance Commentary
Scientific Knowledge on the Subject: Rifamycins are key sterilizing agents for tuberculosis treatment, but recommended doses are at the low end of the dose-response curve. Optimizing rifamycin dose and exposure is a strategy for optimizing regimen potency and shortening duration of therapy required for cure. Rifapentine, a ring-substituted rifamycin, has potent antituberculosis activity when administered daily in animal models, but its optimal dose and exposure in humans is unknown.
What This Study Adds to the Field: In this phase 2 study, the substitution of high-dose daily rifapentine for rifampin improved the antimicrobial activity of combination chemotherapy during the intensive phase of pulmonary tuberculosis treatment, and this activity was driven by rifapentine exposure. The observed safety and tolerability, high levels of antimicrobial activity observed in the groups with the higher rifapentine exposures, magnitude of the activity differences versus rifampin, and consistency across end points and media types provide support for the evaluation of high-dose daily rifapentine-containing regimens of less than 6 months duration in phase 3 clinical trials.
Tube (MGIT; Becton Dickinson and Co., Franklin Lakes, NJ) liquid media with the MGIT 960 system. Each laboratory used its own programmatic source for LowensteinJensen media. M. tuberculosis isolates underwent drug susceptibility testing at site laboratories; confirmatory testing for all isolates was performed at a single laboratory using the indirect agar proportion method for isoniazid, rifampin, and ethambutol, and MGIT medium for pyrazinamide.
Pharmacokinetic Analysis
Pharmacokinetic sampling was performed 3-8 weeks after treatment initiation. Intensive pharmacokinetic sampling (seven samples over 24 h) was performed at designated sites with capacity to do so; for other participants, one to three samples were obtained. Plasma concentrations of rifapentine were determined by a validated high-pressure liquid chromatography method in a single laboratory (26) . Population pharmacokinetic models were developed using nonlinear mixed effects modeling (NONMEM, version 7; ICON plc, Dublin, Ireland) (27, 28) . Post hoc Bayesian estimates of individual areas under the concentration-time curve (AUC) were derived from the models.
Data Analysis
A "well-tolerated" regimen was prespecified as one for which the upper bound of the 90% one-sided confidence interval of the percentage of participants discontinuing treatment during intensive phase was less than 30% (twice the rate observed for the rifampin regimen in prior Tuberculosis Trials Consortium studies) (29, 30) . Using the Clopper-Pearson method we calculated that a sample size of 70 microbiologically eligible participants per arm was required to assess tolerability (31) . To obtain 70 microbiologically eligible participants per arm, target enrollment was 80 per arm (320 total) to account for baseline cultures that grew drug-resistant M. tuberculosis or were negative for M. tuberculosis growth; confidence intervals were constructed from observed data using the Wilson score method (32) .
Culture status was considered to be negative at completion of intensive phase if neither of the two sputa collected at that time grew M. tuberculosis. Stable culture conversion was defined as having occurred at the time of collection of the first of two consecutive specimens, collected at least 2 weeks apart, that were culture-negative for M. tuberculosis, with no subsequent specimen culture-positive for M. tuberculosis. The intention-to-treat analysis group was comprised of all randomized participants and was used for tolerability and safety analyses. For efficacy analyses, a modified intention-to-treat (MITT) group included participants with growth in a baseline culture of M. tuberculosis that was susceptible to isoniazid, rifampin, and pyrazinamide. For MITT efficacy analyses of culture status at completion of intensive phase, participants with cultures that were missing or contaminated were considered as failures. For efficacy analyses a per-protocol subset of the MITT group was defined as participants who completed assigned intensive phase treatment (56 doses within 56-70 calendar days) and had an end of intensive phase culture that was evaluable (i.e., not missing or contaminated). The primary efficacy analysis was by assigned treatment group; secondary analyses were performed by dosage (in milligrams) of rifapentine administered and by rifapentine AUC tertile.
Differences in the percentage of participants found to be culture-negative at the end of intensive phase were calculated comparing each rifapentine group with the rifampin group; confidence intervals for differences between arms were constructed using the Wald method. We assessed differences in time to stable culture conversion visually by graphing the KaplanMeier product-limit estimates at Days 15, 29, 43, 57, 85 , and 113 after start of therapy, and we compared them formally with the log-rank test extended to interval-censored data (33, 34) . Calculations were performed in SAS (v 9.3; SAS Institute, Cary, NC) and R (v 2.12; R Development Core Team, Vienna, Austria).
Results
Between November 2011 and October 2012, 334 participants were enrolled ( Figure 1 ). Table 1 shows participant characteristics at enrollment. A total of 190 of 334 (56.9%) were enrolled at African sites, 26 of 334 (7.8%) had HIV, and 257 of 334 (77.0%) had cavitation on baseline chest radiograph. By chance, the rifapentine 20 mg/kg group contained a larger percentage of HIVinfected persons (13.6%) than the other groups.
Tolerability and Safety
Percentages of participants discontinuing assigned treatment during the first 8 weeks, by arm, were as follows: rifampin, 12.9% (11 of 85; upper bound of the 90% one-sided confidence interval, 19.0%); rifapentine 10 mg/kg, 5.7% (5 of 87; 10.5%); rifapentine 15 mg/kg, 6.2% (5 of 81; 11.3%); and rifapentine 20 mg/kg, 11.1% (9 of 81; 17.1%) ( Table 2 ). None of the upper 90% confidence intervals exceeded the prespecified 30% rate for unacceptable tolerability, and 40% of all discontinuations were caused by newly demonstrated microbiologic ineligibility (i.e., absence of M. tuberculosis growth in baseline cultures or the presence of initial drug resistance). There were two deaths, one in the rifapentine 15 mg/kg group attributed to TB and one in the rifapentine 20 mg/kg group from sudden death; neither was attributed to study treatment. Discontinuation of assigned treatment because of toxicity other than death occurred in three participants in the rifampin group (two with hepatitis and one with drug allergy), one participant in the rifapentine 15 mg/kg group (grade 2 nausea), and two participants in the rifapentine 20 mg/kg group (one with hepatitis, one with drug allergy).
Adverse events are shown in Table 2 , with additional detail in Table E3 . There were eight serious adverse events in the rifapentine 20 mg/kg group and three in each of the other groups. Only one (hepatitis) of the serious adverse events in the rifapentine 20 mg/kg group was attributed to study treatment. There were no clinically significant dose-related trends in adverse events among participants who received rifapentine.
Efficacy
Among 334 enrolled participants, 50 were excluded from efficacy analyses because baseline cultures failed to grow M. tuberculosis (n = 6) or grew drugresistant M. tuberculosis (n = 44) (Figure 1 ). In addition, all 30 participants from one site were excluded from efficacy analyses (but not from safety and tolerability analyses); that site had a substantial proportion of culture results that were not evaluable, mainly because of contamination, ORIGINAL ARTICLE precluding interpretation of bacteriologic outcomes.
Efficacy results by assigned treatment group. For the MITT analysis group, 81.3% (52 of 64) of participants in the rifampin group had negative cultures on solid medium at completion of intensive phase versus 92.5% (62 of 67; P = 0.097 vs. rifampin), 89.4% (59 of 66; P = 0.29 vs. rifampin), and 94.7% (54 of 57; P = 0.049 vs. rifampin) in the rifapentine 10, 15, and 20 mg/kg groups (Table 3) , respectively. On liquid media, 56.3% (36 of 64) of participants in the rifampin group had negative cultures versus 74.6% (50 of 67; P = 0.042 vs. rifampin), 69.7% (46 of 66; P = 0.16 vs. rifampin), and 82.5% (47 of 57; P = 0.004 vs. rifampin) in the rifapentine 10, 15, and 20 mg/kg group, respectively. Time to stable culture conversion was significantly shorter for each of the rifapentine arms versus the rifampin arm using solid media, but there were no differences using liquid media (see Table E7 and Figures 2A and 2B ). Similar trends were observed in the per-protocol analysis (see Tables E4 and E8, and Figures  E1A and E1B) .
Efficacy results by administered rifapentine dose (in milligrams). For the MITT analysis group, negative cultures on solid medium at completion of intensive phase occurred in 87.1% (54 of 62; P = 0.51 vs. rifampin), 96.7% (58 of 60; P = 0.015 vs. rifampin), and 89.7% (26 of 29; P = 0.47 vs. rifampin) of participants receiving rifapentine 600, 900, and 1,200 mg, respectively (Table 4) . Negative cultures on liquid media occurred in 75.8% (47 of 62; P = 0.033 vs. rifampin), 75.0% (45 of 60; P = 0.045 vs. rifampin), and 82.8% (24 of 29; P = 0.025 vs. rifampin) of participants receiving rifapentine 600, 900, and 1,200 mg, respectively. Time to stable culture conversion on solid media was significantly shorter for the rifapentine 900-mg arm versus the rifampin arm (see Table E7 and Figures 2C and 2D ). Similar trends were observed in the per-protocol analysis (see Tables E5 and E8, and Figures E1C  and E1D) .
Efficacy results by rifapentine AUC tertile. For the MITT analysis group, negative cultures on solid medium at completion of intensive phase occurred in 83.9% (52 of 62; P = 0.88 vs. rifampin), 100.0% (63 of 63; P , 0.001 vs. rifampin), and 92.3% (60 of 65; P = 0.11 vs. rifampin) in the lowest, mid, and highest rifapentine AUC tertiles, respectively (Table 5) . Negative cultures on liquid media occurred in 54.8% (34 of 62; P = 1.00 vs. rifampin), 90.5% (57 of 63; P , 0.001 vs. rifampin), and 80.0% (52 of 65; P = 0.007 vs. rifampin) in the lowest, mid, and highest rifapentine tertiles, respectively. Time to stable culture conversion was significantly shorter for each of the mid and high rifapentine exposure groups versus the rifampin group (see Table E7 and Figures 2E and 2F) . Results for the rifapentine lowest tertile exposure group and the rifampin group were strikingly similar regardless of the end point or media type; this trend was also observed in the per-protocol analysis (see Tables E6 and E8, and Figures E1E  and E1F ).
Discussion
Results of this dose-ranging study showed that rifapentine doses of up to 20 mg/kg once daily, administered with food to optimize rifapentine absorption and exposure, were well tolerated and safe during the first 8 weeks of combination chemotherapy for pulmonary TB. Although the study was not powered for efficacy, all rifapentine arms achieved high rates of sputum culture conversion at completion of intensive phase. Most strikingly, antimicrobial activity was strongly associated with rifapentine exposure. Among participants with higher rifapentine exposures (AUC >324 mg*h/ml), 80-90% had negative cultures on liquid media at the completion of intensive phase, compared with 56% in the control group in this study and 54-65% in control groups in other recent phase 2 trials conducted by our consortium in similar populations (20, 30) . Is the antimycobacterial activity observed with the higher rifapentine exposures sufficient to achieve durable cure in less than 6 months and thereby shorten the duration of treatment for drugsusceptible pulmonary TB? Previously conducted trials provide some guidance with respect to the use of the surrogate end point of proportion of participants with negative cultures on solid media at completion of intensive phase. In earlier randomized trials conducted by the British Medical Research Council, the addition of pyrazinamide to regimens including isoniazid plus rifampin increased the proportion of participants culture-negative for M. tuberculosis on solid media by an average of 12.7% (range, 7-17%). This increase correlated clinically with the ability to decrease the duration of therapy from 9 months to the current 6 months, while maintaining acceptably low relapse rates (35) (36) (37) (38) (39) (40) (41) . In our study, using this surrogate end point, substituting rifapentine for rifampin (as randomized) increased the proportion of participants culture negative for M. tuberculosis by 8-13%, and the difference was 11-19% when rifapentine AUC was greater than or equal to 324 mg $ h/ml. Therefore, for the higherexposure rifapentine regimens in our study, the potency is in range for shortening treatment based on this surrogate bacteriologic end point.
With respect to selecting the optimal dose of rifapentine to use in a future phase 3 trial of treatment shortening, we first analyzed antimicrobial activity by treatment assignment (as randomized). In solid and in liquid media the percentage with negative cultures was highest in the rifapentine 20 mg/kg group, but there was no clear trend across the rifapentine arms, whether assessed using the end point of culture status at end of intensive phase or time to stable culture conversion. However, pharmacokinetic-pharmacodynamic evaluations provided important insights. Regardless of the efficacy end point, the antimicrobial activity was indistinguishable between participants with rifapentine AUC Definition of abbreviations: ALT = alanine aminotransferase; IQR = interquartile range; MGIT = Mycobacterial Growth Indicator Tube; TB = tuberculosis; ULN = upper limit of normal for the testing laboratory.
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in the lowest tertile compared with participants receiving rifampin. Efficacy was substantially greater in participants with rifapentine AUC values in the second and third exposure tertiles. This suggests that the tested doses of rifapentine resulted in exposures that were on the steep part of the exposure-response curve, a situation similar to that for rifampin at the doses used clinically today (4, 8, 9, 42) .
Interindividual variability in rifapentine pharmacokinetics is substantial, particularly with mg/kg, because weight does not significantly impact rifapentine clearance (27) . In our trial, overlap of Definition of abbreviations: CI = confidence interval by Wilson score method; SAE = serious adverse event.
Hepatitis was defined as transaminases greater than or equal to five times upper limit of normal or greater than or equal to three times upper limit of normal with symptoms, or bilirubin greater than or equal to three times upper limit of normal, or determined by site investigator to have a new diagnosis of hepatitis. exposures may have obscured the relationship between antimicrobial activity and either treatment assignment or administered dose. Because all rifapentine doses in our study seemed to be safe and the limits of tolerability were not reached, the decision as to rifapentine dose to move forward into a phase 3 trial will be made based on efficacy in the Figure 2 . Time to stable culture conversion for the modified intention-to-treat analysis group: by assigned treatment group, and as assessed using solid culture medium (P = 0.010) (A) and liquid culture medium (P = 0.32) (B); by administered rifapentine dose, as assessed using solid culture medium (P = 0.011) (C) and liquid culture medium (P = 0.38) (D); by rifapentine area under the concentration-time curve (AUC) tertile, as assessed using solid culture medium (P , 0.001) (E ) and liquid culture medium (P , 0.001) (F ). The x-axes are the time in study, calculated at baseline and at Days 15, 29, 43, 57, 85 , and 113 (corresponding to Weeks 2, 4, 6, 8, 12 , and 16, respectively). Stable culture conversion was considered to have occurred at the time a sputum specimen was obtained that was found to be negative for Mycobacterium tuberculosis in culture, with at least one additional subsequent sputum that was culture-negative and no subsequent sputa that were culture-positive for M. tuberculosis. RPT = rifapentine.
context of a full pharmacokineticpharmacodynamic model. Fixed dosing in milligrams, not mg/kg, will be used to reduce variability in exposures and a dose will be selected that ensures that most participants reach target AUC, especially given that therapeutic drug monitoring is not feasible in most high TB burden settings.
It is worth noting that two recent phase 3 clinical trials failed to demonstrate noninferiority of daily 4-month TB regimens that substituted a fluoroquinolone for ethambutol (43, 44) . Leading up to that phase 3 trial, three phase 2 studies substituting a fluoroquinolone for ethambutol had shown inconsistent results with respect to the differences (between investigational and control arms) in percentages of participants with negative cultures on solid media at completion of intensive phase, differences of 0-18% (29, 45, 46) . One of these studies also incorporated liquid media MGIT cultures and reported statistically nonsignificant differences of 4-8% between investigational and control arms in percentages of participants with negative cultures on liquid media at completion of intensive phase (45) . In our study the groups with the higher rifapentine exposures had very high percentages of participants with negative cultures in liquid media at completion of intensive phase (80.0-90.5%) corresponding to differences versus rifampin of 23.8-34.2%. Although liquid culture has not been well-validated for use as a surrogate marker for durable cure, the robustness of our results is encouraging. Additionally, in our study, it is reassuring that results were consistent for both culture media used, both bacteriologic end points assessed (i.e., culture status at end of intensive phase and time to stable culture conversion), and in both the MITT and per-protocol analysis groups.
A limitation of our study is that we did not investigate rifapentine doses above 20 mg/kg; the highest dose administered in our study was 1,500 mg daily. However, several lines of evidence suggest that the optimal rifapentine dose is unlikely to be substantially greater than approximately 1,200 mg daily. A study of the early bactericidal activity of rifapentine showed an apparent maximal bactericidal effect between doses of 900 and 1,200 mg (8) . Preliminary pharmacodynamic modeling of our results also showed that the maximal improvement in efficacy with rifapentine substitution for rifampin was achieved at rifapentine AUC values between the medians for 900 and 1,200 mg daily doses (28) . With respect to tolerability, in a phase 1 study of healthy volunteers administered daily rifapentine, five of seven (71%) participants who received 1,800 mg discontinued drug early because of toxicity (47) . In our study, we administered rifapentine-containing regimens with a high-fat meal to increase bioavailability (25) . We used staple foodstuffs readily available in the communities in which the trial was conducted. Whether provision of food with drug doses would be feasible in routine practice is uncertain.
To be programmatically relevant, the dose selection for rifapentine in phase 3 trials should take into account the fact that patients may or may not take their doses with food under routine conditions. HIV-positive individuals who were on antiretroviral therapy or in whom antiretroviral therapy was indicated were underrepresented, thereby limiting generalizability of our findings in this group. Ongoing work to characterize drug-drug interactions between rifapentine and antiretroviral agents may help to identify strategies for using rifapentine with certain antiretrovirals. There was no blinding with respect to rifampin versus rifapentine, and this could have had an impact on tolerability.
We conclude that the substitution of high-dose daily rifapentine for rifampin improves the antimicrobial activity of combination chemotherapy during the intensive phase of pulmonary TB treatment, and that this activity is driven by rifapentine exposure. The observed safety and tolerability, high levels of antimicrobial activity observed in the groups with the higher rifapentine exposures, magnitude of the activity differences versus rifampin, and consistency across end points and media types provide support for the evaluation of high-dose daily rifapentinecontaining regimens of less than 6 month duration in phase 3 clinical trials of durable cure. n Author disclosures are available with the text of this article at www.atsjournals.org.
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